Literature DB >> 20009463

[Successful gefitinib every other day administration in an advanced lung cancer patient with brain metastasis after gamma knife radiotherapy and chemotherapy].

Shinichi Tomisaki1, Tomoyoshi Takenaka, Goki Morizono, Tatsuya Tanaka, Nobuaki Momosaki, Fumio Inoue.   

Abstract

A 69-year-old female, who had been admitted to another hospital with a complaint of headache and there detected brain tumor, was referred to our hospital for further examination and therapy. The patient was diagnosed as having advanced lung cancer with multiple brain metastasis. She was treated with five courses of a combination of chemotherapy consisting of carboplatin and paclitaxel following gamma knife radiotherapy. She showed a remarkable response, however, she experienced the side effects of general fatigue and numbness in her extremities, which were intolerable. Then, therapy with gefitinib alone was chosen as second-line chemotherapy. After one month, this therapy was discontinued due to grade 3 skin trouble and rash. When her condition improved, every other day oral administration of gefitinib was resumed. She has been treated on an outpatient basis because of no severe adverse reactions. The patient is alive with good performance status (PS) 0 more than one year after taking gefitinib. Furthermore, the primary and metastatic tumors are not enlarged. Gefitinib orally administered every other day could be a promising regimen as second-line chemotherapy for patients with lung cancer and brain metastasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20009463

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report.

Authors:  Hiroko Watanabe; Tomohiro Tamura; Katsunori Kagohashi; Norio Takayashiki; Koichi Kurishima; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Exp Ther Med       Date:  2015-05-18       Impact factor: 2.447

2.  Successful erlotinib treatment for a patient with gefitinib-related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib.

Authors:  Tatsuya Nagano; Yoshikazu Kotani; Kazuyuki Kobayashi; Masahiro Katsurada; Yukihisa Hatakeyama; Suya Hori; Daisuke Tamura; Daisuke Kasai; Yasuhiro Funada; Yoshihiro Nishimura
Journal:  Case Rep Pulmonol       Date:  2011-12-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.